▼ Summary
– In September, the Trump administration promoted the generic drug leucovorin as a promising treatment for autism, with FDA Commissioner Marty Makary making bold claims about its potential benefit.
– Following this promotion, a study found new outpatient prescriptions of leucovorin for children aged 5-17 increased by 71% in the subsequent three months.
– The FDA has now clarified it does not share the administration’s view, approving leucovorin only for a rare genetic condition, not for autism.
– Senior FDA officials stated they found little evidence to support expanding the drug’s use to treat autism.
– The approved use is specifically for cerebral folate deficiency (CFD) in adults caused by a genetic mutation (CFD-FOLR1).
The recent decision by the U.S. Food and Drug Administration to reject the use of generic leucovorin for treating autism spectrum disorder marks a significant departure from earlier claims made by the previous administration. This move clarifies the regulatory stance on the drug’s approved uses, emphasizing that current scientific evidence does not support its broad application for autism. The agency’s focus remains on validated treatments, ensuring patient safety and efficacy based on rigorous review standards.
Last September, officials within the Trump administration promoted leucovorin as a potential breakthrough for autism. FDA Commissioner Marty Makary publicly suggested the drug could benefit a substantial percentage of children with the condition, estimating it might help “20, 40, 50 percent of kids with autism.” He further asserted that “hundreds of thousands of kids, in my opinion, will benefit.” These statements were part of what the administration labeled “bold actions” aimed at addressing autism.
The promotional efforts appear to have had a direct impact on prescribing patterns. Research published in The Lancet indicated a sharp increase in leucovorin prescriptions for children aged five to seventeen in the months following the administration’s announcements. Specifically, new outpatient prescriptions for this age group surged by seventy-one percent over a three-month period, highlighting how official endorsements can rapidly influence medical practice.
However, the FDA’s latest announcement presents a contrasting position. The agency has officially approved leucovorin solely for treating a specific rare genetic disorder, not for autism. This approved use is for cerebral folate deficiency in adults, a condition caused by a particular genetic mutation known as CFD-FOLR1. By narrowing the scope of its review, the regulatory body has effectively countered the earlier, broader claims about the drug’s utility.
Senior FDA officials explained their decision to the Associated Press, noting a lack of compelling evidence to justify expanding the drug’s label to include autism treatment. Their evaluation concluded that the available data did not meet the necessary thresholds for safety and effectiveness for that application. This underscores the agency’s commitment to a science-driven approval process, distinct from political or promotional narratives.
The divergence between the earlier enthusiastic endorsements and the final regulatory outcome illustrates the complex interplay between public health communication and evidence-based medicine. While public figures may highlight emerging possibilities, the FDA’s role is to ensure that all approved treatments are backed by substantial scientific proof. This case serves as a reminder that official statements from political figures do not equate to regulatory endorsement, and final decisions rest on thorough evaluation by the agency’s scientific experts.
For families and clinicians, this development reinforces the importance of relying on approved indications and consulting robust clinical guidelines. The FDA’s clear delineation helps direct appropriate use of leucovorin towards patients with the specific genetic deficiency it is proven to address, while avoiding off-label use for autism without sufficient supporting data. The medical community continues to seek and evaluate new treatments, but this process remains firmly grounded in methodological research and regulatory scrutiny.
(Source: Ars Technica)
